Fulcrum Insights/Market Analysis

Private Equity's Impact on Healthcare Reimbursement

Consolidation has changed who sits across the negotiating table — and how reimbursement is won, defended, and scrutinized.

Private-equity investment has reshaped physician services, from emergency medicine and radiology to dermatology, gastroenterology, and ophthalmology. The reimbursement consequences are real: greater negotiating scale, more sophisticated contracting, heightened payer and regulatory attention, and a No Surprises Act framework built partly in response to out-of-network billing practices. This brief separates the reimbursement signal from the political noise.

Focus
Consolidation & reimbursement
Audience
Investors, boards, group leaders
Read
6 min
Prepared
2026

Scale changed the leverage math

The clearest reimbursement effect of consolidation is negotiating scale. A single-site practice negotiates one contract against a national payer's portfolio-level data. A platform spanning dozens of sites negotiates with volume, geographic coverage, and analytics that approach the payer's own. That shift alone can move commercial rates materially, particularly in specialties where the platform controls a large share of a local market.

But scale cuts both ways. The same market concentration that improves leverage also draws antitrust attention, payer network-design responses, and, in hospital-based specialties, the No Surprises Act's constraints on out-of-network billing.

So What

Reimbursement gains from consolidation are durable only when they rest on demonstrated value and clean contracting — not on out-of-network leverage that the No Surprises Act has largely closed.

The No Surprises Act reset the model

Several PE-backed staffing models historically relied, in part, on out-of-network billing for hospital-based services. The No Surprises Act removed the patient from that equation and routed disputes into the Federal Independent Dispute Resolution (IDR) process, anchored to the qualifying payment amount (QPA). For emergency medicine, radiology, anesthesiology, and pathology, that changed the economics of the underlying investment thesis.

The result is a sharper focus on in-network rate strategy, QPA integrity, and disciplined use of IDR — rather than balance-billing leverage — as the path to fair reimbursement.

What payers and regulators are watching

Illustrative scrutiny map — consolidated provider platforms
AreaWhat draws attentionReimbursement implication
Market concentrationHigh local share in a specialtyAntitrust review; payer network pushback
Out-of-network patternsIDR volume, QPA disputesRate compression; administrative cost
Coding intensityUpcoding / modifier patternsAudit exposure; denials
Site-of-serviceFacility vs office billing mixPayer steering; site-neutral pressure

Illustrative; specifics vary by state, specialty, and payer.

None of these is disqualifying, but each is a place where reimbursement can be gained through discipline or lost through inattention.

A reimbursement thesis that survives diligence

How Fulcrum Helps

Reimbursement diligence and rate strategy for consolidated platforms

Fulcrum Health Partners supports investors and management teams before and after close — quantifying reimbursement risk, protecting negotiated rates, and building a defensible contracting posture.

Underwrite the rate, not just the multiple.

We help investors and management teams pressure-test reimbursement before close and protect it after. Reach the Fulcrum team to scope a reimbursement diligence engagement.

About this article. Prepared by Fulcrum Health Partners as an educational summary. Figures attributed to public sources (CMS, KFF, MedPAC, RAND, DOL) reflect the most recent data available at the time of writing; figures labeled illustrative are directional and should be validated against your own contract and claims data before use. This document is not legal, reimbursement, tax, or actuarial advice. © 2026 Fulcrum Health Partners.

Back to all Insights